|By Marketwired .||
|June 20, 2014 05:00 PM EDT||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/20/14 -- RepliCel Life Sciences Inc. (TSX VENTURE:RP)(OTCQB:REPCF), today announced that it has retained O&M Partners, LLC to assist in targeting non-deal institutional and independent money managers throughout the United States including financial centres often overlooked by biotech companies. This marketing effort will include a combination of group Town Hall conference calls and follow-up roadshows. With the commencement of three human clinical trials before year-end, management is dedicated to meeting as many non-deal investors as possible. This campaign is an integral part of the company's overall marketing effort focused on the United States.
O&M Partners, LLC is internationally recognised by institutional and independent money managers for its ability to discover high-potential companies, identify sector trends, and qualify market sentiment. Since 1995, O&M's New York-based marketing professionals have been bringing Wall Street together with the senior management of publicly traded companies on the TSX, AMEX and NASDAQ. O&M specializes in non-deal institutional marketing of micro-and small-caps.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function such as chronic tendinosis, damaged skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies are designed to treat chronic tendinosis and damaged or aging skin respectively, using fibroblasts isolated from the sheath of the hair follicle. Another of the company's pipeline products, RCH-01 for the treatment of pattern baldness, is manufactured from cells derived from the hair follicle dermal cup. Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. For additional information please visit www.replicel.com.
On Behalf of the Board
RepliCel Life Sciences Inc.
David Hall, President and Chief Executive Officer
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
RepliCel Life Sciences
Tammey George, Director of Communications
US INVESTOR RELATIONS:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
CANADIAN INVESTOR RELATIONS:
What are the successful IoT innovations from emerging markets? What are the unique challenges and opportunities from these markets? How did the constraints in connectivity among others lead to groundbreaking insights? In her session at @ThingsExpo, Carmen Feliciano, a Principal at AMDG, will answer all these questions and share how you can apply IoT best practices and frameworks from the emerging markets to your own business.
Jul. 23, 2016 03:45 PM EDT Reads: 1,483
Basho Technologies has announced the latest release of Basho Riak TS, version 1.3. Riak TS is an enterprise-grade NoSQL database optimized for Internet of Things (IoT). The open source version enables developers to download the software for free and use it in production as well as make contributions to the code and develop applications around Riak TS. Enhancements to Riak TS make it quick, easy and cost-effective to spin up an instance to test new ideas and build IoT applications. In addition to...
Jul. 23, 2016 03:30 PM EDT Reads: 1,826
Jul. 23, 2016 03:15 PM EDT Reads: 753
Jul. 23, 2016 03:00 PM EDT Reads: 1,164
Jul. 23, 2016 03:00 PM EDT Reads: 1,641
Jul. 23, 2016 02:30 PM EDT Reads: 1,695
Jul. 23, 2016 02:15 PM EDT Reads: 613
Jul. 23, 2016 02:00 PM EDT Reads: 998
Jul. 23, 2016 01:45 PM EDT Reads: 472
Jul. 23, 2016 01:15 PM EDT Reads: 706
Jul. 23, 2016 01:00 PM EDT Reads: 806
Jul. 23, 2016 12:00 PM EDT Reads: 814
Jul. 23, 2016 12:00 PM EDT Reads: 1,108
Jul. 23, 2016 11:00 AM EDT Reads: 1,136
Jul. 23, 2016 11:00 AM EDT Reads: 1,814